- Poster presentation
- Open Access
Ezetimibe as lipid-lowering therapy for patients receiving HAART
© Asghar et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Protease Inhibitor
- Total Cholesterol
- Lipid Metabolism
Dyslipidaemia in HIV has been linked with both a cytokine-driven lipid metabolism re-arrangement in significant viraemia, and with the use of highly-active antiretroviral therapy (HAART), especially protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
This study was a retrospective review, evaluating the efficacy and safety of Ezetimibe in our cohort of HIV-positive patients stable on HAART with dyslipidaemia. Out of the 29 such individuals prescribed 10 mg Ezetimibe once daily, 17 received it in addition to a statin, and 12 received it as a direct replacement for a statin.
Prior to initiation of Ezetimibe, median serum total cholesterol and triglyceride levels were 6.3 mmol/l (range: 3.6–10.7) and 2.9 mmol/l (range: 0.54–13.02), respectively. Review of the lipid profiles of the cohort after 12 weeks of Ezetimibe therapy revealed (see data in Figure 1). Two individuals discontinued Ezetimibe prematurely.
- Coll B, et al: Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006, 20: 1675-7.PubMedView ArticleGoogle Scholar
- Negredo E, et al: Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006, 20: 2159-64.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd.